Table A4.6 Threshold analysis to identify extreme values of parameters that make the ICER for vertebroplasty cost-effective (i.e. < £20,000), with questionable cost-effectiveness (i.e. £20,000– £30.000), or no cost-effective (i.e. > £30,000), compared to no treatment, under the ideal scenario and under scenario 2.

ICER ≤ £20,000ICER: £20,000–£30,000ICER ≥ £30,000
Ideal scenario
Proportion of ambulatory patients≥ 0.18360.1649–0.1836≤ 0.1649
Survival for post-treatment patients (in months, modifying jointly time to paraplegia)≥ 2.852.58–2.85≤ 2.58
Time to paraplegia for post-treatment ambulant patients (in months)≥ 4.504.18–4.50≤ 4.18
Survival for non-ambulant patients (in months) as a proportion of the ambulant≥ 1.14≤ 1.14SNF
Scenario 2
Proportion of ambulatory patients≥ 0.27150.2413–0.2715≤ 0.2413
Survival for post-treatment patients (in months, modifying jointly time to paraplegia)≥ 4.063.63–4.06≤ 3.63
Time to paraplegia for post-treatment ambulant patients (in months)≥ 4.273.97–4.27≤ 3.97
Survival for non-ambulant patients (in months) as a proportion of the ambulant (Scenario 3)≥ 6.986.01–6.98≤ 6.01
Daily costs of home care for non-ambulant patients (£)SNFSNFSNF
Costs of treatment (£)≤ 2666626666–29862≥ 29862

SNF = Solution not found

From: Appendix 4, An economic evaluation of treatments for people with suspected metastatic spinal cord compression

Cover of Metastatic Spinal Cord Compression
Metastatic Spinal Cord Compression: Diagnosis and Management of Patients at Risk of or with Metastatic Spinal Cord Compression.
NICE Clinical Guidelines, No. 75.
National Collaborating Centre for Cancer (UK).
Copyright © 2008, National Collaborating Centre for Cancer.

No part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licenses issued by the Copyright Licensing Agency in the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.